Nan Wang

Nan Wang

Auto-generated profile, based on publicly available information

Nan Wang

Department of Neurosurgery, Beijing Tiantan Hospital Capital Medical University Beijing China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
XLXiaomeng Li
Xiaomeng Li
LSLi Sun
Li Sun
XWXue Wang
Xue Wang
NWNan Wang
Nan Wang
KXKanghong Xu
Kanghong Xu
SXShuo Xu
Shuo Xu
Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the glioblastoma microenvironment. Thus, the study of immune-related long noncoding RNA (lncRNA) signature is of great value in the diagnosis, treatment, and prognosis of glioblastoma.Methods: Glioblastoma samples with lncRNA sequencing and corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. Immune-lncRNAs co-expression networks were built to identify immune-related lncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related lncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis.Results: A cohort of 151 glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this lncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses.Conclusions: Our study proposes that a five immune-related lncRNA signature can be utilized as a latent indicator of prognosis and potential therapeutic approach for glioblastoma.

5 December 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
NWNan Wang
Nan Wang
XCXiaoke Chai
Xiaoke Chai
JSJiuxiang Song
Jiuxiang Song
YHYifang He
Yifang He
QHQiheng He
Qiheng He
JZJizong Zhao
Jizong Zhao
Objective: The current application of single‐modality electroencephalography (EEG) or functional near‐infrared spectroscopy (fNIRS) to assess consciousness levels in patients with disorders of consciousness (DoC) has garnered significant attention. However, the diagnostic accuracy of unimodal approaches remains suboptimal. Therefore, this study aims to apply the multimodal fusion technology of EEG and fNIRS to the clinical diagnosis of DoC patients. Methods: Eleven patients with DoC (six with a minimally conscious state [MCS] and five with a vegetative state [VS]) were enrolled. The motor intention‐based brain‐computer interface (MI‐BCI) paradigm was adopted. EEG and fNIRS were recorded simultaneously. The synchronous states of EEG and fNIRS were analyzed, including time‐frequency analysis, event‐related desynchronization (ERD), and changes in oxy‐hemoglobin (HbO)/de‐oxygenated (HbR)/total hemoglobin (HbT) content. A multimodal method combining EEG and fNIRS was used to classify DoC patients. Results: The machine‐learning results of the MI‐BCI model showed that the EEG‐fNIRS multimodal approach was superior to single‐modality techniques in the diagnosis of healthy controls (HC), MCS, and VS. The multimodal model achieved a mean AUC of 0.69 ± 0.10, significantly outperforming both unimodal EEG (0.43 ± 0.19; p < 0.01) and standalone fNIRS (0.63 ± 0.10; p < 0.05). The EEG_ERD index of left‐handed MI‐BCI significantly differentiated the MCS and VS groups. Meanwhile, for the classification tasks of HC, MCS, and VS, the importance ranking of the indicators was as follows: fNIRS_ACC, EEG_ACC, fNIRS_slope, fNIRS_centroid, EEG_ERD, fNIRS_integral, and fNIRS_mean. Conclusion: The integration of multimodal MI‐BCI paradigms demonstrates clinical potential in evaluating consciousness levels, while the synergistic combination of neurophysiological and hemodynamic biomarkers provides a robust framework for enhancing the precision of bedside diagnostic protocols. Trial Registration: Clinical Trial Registry: ChiCTR2400085830

6 March 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
TCTianqing Cao
Tianqing Cao
XCXiaoke Chai
Xiaoke Chai
HWHongbin Wu
Hongbin Wu
NWNan Wang
Nan Wang
JSJiuxiang Song
Jiuxiang Song
JZJizong Zhao
Jizong Zhao
Background: The heart rate variability (HRV) of patients with disorders of consciousness (DOC) differs from healthy individuals. However, there is rarely research on HRV among DOC patients following treatment with deep brain stimulation (DBS). This study aims to investigate the modulatory effects of DBS‐on the central‐autonomic nervous system of DOC based on the study of HRV variations.Methods: We conducted DBS surgery on eight patients with DOC. Postoperatively, all patients underwent short‐duration stimulation for 3 days, with stimulation frequencies of 25 Hz, 50 Hz, and 100 Hz respectively. Each day comprised four cycles, with a stimulation duration of 30 min DBS‐on and 90 min DBS‐off. We obtained the coma recovery scale‐revised (CRS‐R) scores and synchronously recorded electrocardiographic data.Resulits: We analyzed the HRV indices, including time‐domain and frequency‐domain parameters across various time points for all patients. The HRV exhibited a consistent trend across the three groups with different parameters. Notably, the most pronounced HRV changes were induced by the 100 Hz. Long‐term follow‐up indicates that high‐frequency (HF), low‐frequency (LF), and total power (TP) of HRV may serve as predictive indicators in the prognosis of patients.Conclusion: Our study reveals that DBS enhances DOC patient consciousness while increasing HRV. Specifically, frequency‐domain indices correlate with favorable prognosis.

10 December 2025 in Medcomm
Verified
Journal Article
Open access
NWNan Wang
Nan Wang
JSJuanning Si
Juanning Si
YHYifang He
Yifang He
JSJiuxiang Song
Jiuxiang Song
XCXiaoke Chai
Xiaoke Chai
JZJizong Zhao
Jizong Zhao
The diagnosis and management of disorders of consciousness (DoC) remain a critical challenge in clinical medicine and neuroscience. The key bottleneck is the lack of reliable biomarkers and an incomplete understanding of the pathophysiological mechanisms that underlie DoC. In view of this, a bedside‐compatible, multimodal technique based on electroencephalography (EEG) and functional near‐infrared spectroscopy (fNIRS) was utilized to simultaneously capture neuronal oscillations and accompanying hemodynamics, so as to explore neurovascular biomarkers that can effectively discriminate different states of DoC. Resting‐state EEG‐fNIRS data from 13 regions of interest (ROIs) were acquired and compared across healthy controls (HC), minimally conscious state (MCS), and unresponsive wakefulness syndrome (UWS) groups. Hemodynamics‐based functional connectivity and the spectral power of neuronal activity were quantified and subsequently employed to interrogate neurovascular coupling. The results demonstrated significantly stronger neurovascular coupling and beta‐band power in premotor and Broca's areas of the MCS group. A multimodal classifier achieved an accuracy of 87.9% in distinguishing between MCS and UWS. The noninvasive, bedside‐suitable nature of this tool underscores its potential for routine monitoring and prognostic assessment in DoC, addressing a critical need for accessible and reliable biomarkers in both neurology and intensive‐care practice.

20 October 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
HNHaodong Niu
Haodong Niu
YZYilin Zhang
Yilin Zhang
NWNan Wang
Nan Wang
XCXiaoke Chai
Xiaoke Chai
YZYiyi Zhai
Yiyi Zhai
JZJizong Zhao
Jizong Zhao
Background: Disorders of consciousness (DoC), including the vegetative state/unresponsive wakefulness syndrome (VS/UWS) and the minimally conscious state (MCS), present a major clinical challenge due to limited therapeutic options. Trigeminal nerve stimulation (TNS) has recently emerged as a promising neuromodulatory intervention. Mechanisms and Current Evidence: The trigeminal nuclei send efferent fibers to the thalamus and the ascending reticular system, which then broadly innervate multiple brain areas via the ascending reticular activating system (ARAS) through both direct and indirect pathways. Capitalizing on the trigeminal nerve's distinctive anatomy, TNS has been hypothesized to potentially promote consciousness recovery in preclinical models by activating specific pathways, modulating the release of key neurotransmitters (e.g., hypocretin, dopamine, and norepinephrine), and influencing cerebral hemodynamics. Furthermore, randomized controlled trials (RCTs) involving both external TNS (eTNS) and acoustic‐electric TNS have highlighted a possible direction for its application as a novel therapy for DoC; the findings appear to suggest potential clinical relevance, although current evidence remains constrained by small samples, patient heterogeneity, variable stimulation protocols, and limited long‐term follow‐up. Challenges: The clinical translation of TNS, however, faces pressing obstacles, including uncertainty regarding optimal stimulation targets and parameters, insufficient long‐term safety and efficacy data, incompletely elucidated mechanisms of action, and a lack of suitable preclinical models. Conclusions: TNS may represent a promising therapeutic approach for DoC, but further high‐quality studies are needed to establish its mechanisms, safety, efficacy, and optimal stimulation strategies.

6 September 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
YZYichen Zhou
Yichen Zhou
TCTianqing Cao
Tianqing Cao
SZSipeng Zhu
Sipeng Zhu
QHQiheng He
Qiheng He
YJYitong Jia
Yitong Jia
YYYi Yang
Yi Yang
Background: Disorders of consciousness (DoC) lack an integrated framework to guide neuromodulation. This review updates three hierarchical frameworks—ARAS, mesocircuit, and ICNs—and maps therapeutic targets within each. Methods: We synthesized recent neuroanatomical, optogenetic, neuroimaging, and clinical trial evidence, reevaluating classic frameworks and proposing a hierarchical integration to inform multi‐target strategies. Results: Three major updates are identified. In ARAS, glutamatergic neurons in PPN/LDT and parabrachial nucleus, rather than cholinergic neurons, are the primary arousal drivers; clinical translation relies on peripheral nerve stimulations with variable efficacy. The mesocircuit is expanded from a unidirectional GPi‐mediated pathway to a bidirectional GPi–GPe balance modulated by dopamine and adenosine; DBS targeting CM‐Pf/CL shows ~44.7% response rate (38/85) but lacks RCTs, whereas amantadine remains the sole Level 1 evidence. Within ICNs, the executive control network has the strongest RCT support, though efficacy depends on etiology and consciousness level; salience network stimulation is untested. These frameworks are hierarchically integrated: ARAS sustains wakefulness, mesocircuit enables cortical activation, and ICNs support conscious content. Conclusion: Future strategies should adopt multi‐target, multi‐level approaches grounded in individualized network profiling. Priorities include large‐scale RCTs for DBS and stratified protocols based on etiology and consciousness level.